Parithera

Switzerland
Malters, Lucerne, Switzerland, 1015

Company profile

Parithera company profile

Precision oncology includes new ways of treating cancer such as targeted therapies and immunotherapies. These approaches are more specific and effective than current treatments. In the near future, they will considerably reduce worldwide cancer burden. As of today, only a fraction of the 18 million yearly diagnosed patients benefit from precision oncology. To increase the number of beneficiaries, new diagnostic tools are needed to match the specific needs of precision oncology to define patients' eligibility and monitor treatment response.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2021-01-01, Year

Headquarters

Postal code
1015
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
2
Last funding
Grant / $98,609 / 2023-10-05
Investors
2
Lead investors
2
Founders
2
Articles
5

Categories and groups

Founders and investors

Founders

Antoine HerzogWeida Chen

Lead investors

BiopôleFederal Polytechnic School of Lausanne

Investors

BiopôleFederal Polytechnic School of Lausanne